DJT TRUMP TIMEDJT broke out
buy at $40.00-$35.00
take profit1-$45.00
take profit 2-$50.00
take profit3-$55.00
take profit 4-$65.00
Stocksignals
PGHL searching for a breakout.Procter & Gamble Health Limited is one of India’s largest VMS Companies manufacturing and marketing over-the-counter products, vitamins, minerals, and supplements products for a healthy lifestyle and improved quality of life.
Procter & Gamble Health Ltd. CMP is 5258.5. The Positive aspects of the company are Company with No Debt, Company with Zero Promoter Pledge and Growth in Net Profit with increasing Profit Margin. The Negative aspects of the company are high Valuation (P.E. = 40.1).
Entry can be taken after closing above 5264. Targets in the stock will be 5333 and 5477. The long-term target in the stock will be 5565 and 5600+. Stop loss in the stock should be maintained at Closing below 5156 or 4956 depending on your risk taking ability.
Disclaimer: The above information is provided for educational purpose, analysis and paper trading only. Please don't treat this as a buy or sell recommendation for the stock or index. We do not guarantee any success in highly volatile market or otherwise. Stock market investment is subject to market risks which include global and regional risks. I or my clients might have positions in the stocks that we mention in our posts. We will not be responsible for any Profit or loss that may occur due to any financial decision taken based on any data provided in this message. Do consult your investment advisor before taking any financial decisions. Stop losses should be an important part of any investment in equity.
Delta Corp forming a bottom. Delta Corp. Ltd. (India) engages in the business of gaming and entertainment. The firm owns and manages casinos in India. It operates through the following segments: Gaming, Online Skill Gaming, and Hospitality.
Delta Corp. Ltd. (India) CMP is 118.93. The Positive aspects of the company are Moderate Valuation (P.E. = 20.5), Company with No Debt, Company with Zero Promoter Pledge, The Negative aspects of the company are Increasing Trend in Non-Core Income, Declining Net Cash Flow : Companies not able to generate net cash, Companies with growing costs YoY for long term projects and De-growth in Revenue and Profit.
Entry can be taken after closing above 125.25. Targets in the stock will be 125, 129, 131 and 141. The long-term target in the stock will be 149 and 156. Stop loss in the stock should be maintained at Closing below 108 or 104 depending on your risk taking ability.
Disclaimer: The above information is provided for educational purpose, analysis and paper trading only. Please don't treat this as a buy or sell recommendation for the stock or index. We do not guarantee any success in highly volatile market or otherwise. Stock market investment is subject to market risks which include global and regional risks. I or my clients might have positions in the stocks that we mention in our posts. We will not be responsible for any Profit or loss that may occur due to any financial decision taken based on any data provided in this message. Do consult your investment advisor before taking any financial decisions. Stop losses should be an important part of any investment in equity.
What is an ETF? | The Modern Investor’s Secret WeaponWhy ETFs Are Like a Financial Swiss Army Knife ?
Warren Buffett famously stated that 90% of his wife’s inheritance would go into one simple investment: a low cost S&P 500 index fund, likely an ETF (Exchange Traded Fund). ETFs, which now manage over $13 trillion in assets worldwide, combine the benefits of diversification and simplicity by bundling various stocks, bonds, or other assets into a single investment product.
1. Understanding ETFs
ETFs allow you to invest in a collection of assets that often track specific indices, sectors, or asset classes. Key benefits include:
- Diversification: Gain broad exposure without picking individual stocks.
- Liquidity: Trade ETFs like stocks throughout the trading day.
- Transparency: Daily disclosure of holdings ensures clarity about your investments.
Passive investing with ETFs has surged in popularity over active strategies due to lower fees and higher transparency
2. The Impact of Fees
While ETFs are cost effective, they do charge fees (expense ratios).Even small differences in fees can compound significantly over time, reducing long term returns:
- A 0.05% fee might cost $6K over 20 years on a $100K investment growing at 10% annually.
- A 1.00% fee could cost $112K over the same period.
Thus, keeping costs low is critical, especially for long-term investors.
What qualifies as “low cost”?
- Under 0.10%: Very low, often for funds tracking major indices.
- 0.10%–0.25%: Still affordable, typically for niche or strategy-focused ETFs.
- Above 0.50%: High; these funds require careful evaluation to justify their costs.
3. Leading ETF Providers
Major ETF providers dominate the industry:
- BlackRock (iShares): $3.2 trillion AUM, 452 funds, 0.30% average fees.
- Vanguard: $3 trillion AUM, 86 funds, 0.09% average fees, known for reinvesting profits to lower costs.
- State Street (SPDR): $1.5 trillion AUM, 158 funds, 0.27% average fees, creator of the first US-listed ETF (SPY)
4. Top ETFs by Popularity
Some ETFs hold significant assets due to their simplicity, reliability, and low fees :
- S&P 500 funds (SPY, VOO, IVV): Track the largest US companies
- Total US Market (VTI): Covers small, mid, and large-cap US stocks
- Thematic Funds (VUG, VTV): Focus on growth or value stocks
- Nasdaq 100 (QQQ): Heavy on tech companies like Apple and Microsoft
- Bond ETFs (BND, AGG): Represent the US investment-grade bond market
These ETFs serve as essential building blocks for diversified portfolios
5. Concentration in US Markets
US indices like the S&P 500 and Nasdaq 100 are increasingly dominated by a handful of companies:
- The top 10 stocks make up 39% of SPY and 52% of QQQ.
- Companies like Apple, Microsoft, and Amazon account for 34% of the S&P 500.
While this concentration can amplify gains in bull markets, it also increases vulnerability during downturns.
6. Exploring Specialized ETFs
Beyond broad-market funds, ETFs can target specific regions, sectors, or investment strategies. Choosing the right ETF mix depends on your financial goals, time horizon, and risk tolerance. For simplicity, Warren Buffett recommends sticking to an S&P 500 index fund, while globally diversified options like VT are also available.
Final Takeaway
ETFs have revolutionized investing with their low costs, transparency, and accessibility. Whether you're a beginner or a seasoned investor, understanding what's inside the ETF and how it aligns with your strategy is key to building a successful portfolio.
Quantum Corporation: Major Levels to WatchGood morning, trading family!
Quantum Corporation is at a crucial point:
Above $34.50: A breakout could push us to $50 or even higher.
Below $29: The downside opens up to the $6–$12 range.
Stay sharp as these levels could define the next big move.
This Sunday, I’m hosting a Master Your Mind Traders Class to help you build a stronger trading mindset and strategy. Seats are limited—send me a DM for details!
Kris/Mindbloome Exchange
Trade What You See
Micron Technology: Bearish or Ready to Break Out?Good morning, trading family!
Micron (MU) is at an important spot right now:
If we move lower, I’m watching $97 and $96 as key levels, with potential for more downside.
If we hold above $100, there’s room to climb to $102, $103, and $104. A break above $104 could mean a smoother ride higher.
I’m also hosting a Master Your Mind Traders Class this Sunday to help you refine your skills and mindset. Want to join? Send me a message for details.
Kris/ Mindbloome Exchange
Trade What You See
PLTR: Big Move Coming—Key Levels to WatchMorning Trading Family
PLTR is approaching a major decision point.
If the price breaks above $69.57, we could see a strong move up to $92 and beyond.
If the price falls below $66, the downside targets are $57–$59. If these levels don’t hold, watch for $49, $45, $39, and $36.
This is a critical moment—stay prepared for either direction!
Kris/Mindbloome Exchange
Trade What You See
ORACLE Slowly turning into a long-term Buy again.Oracle (ORCL) gave us an excellent buy signal on our last call (September 18 2024, see chart below):
For the past 30 days it has been on a technical decline, which based on its +2 year pattern, is nothing but the Bearish Leg of the Channel Up. The 1W MA50 (blue trend-line) is the natural Support of this trend but the September - October 2023 Bearish Leg bottomed a little over the 0.382 Fibonacci retracement level.
As a result we expect the stock to turn into a buy by the end of the month or if the 1W RSI hits its 42.70 Support first and initiate the new Bullish Leg, which at first shouldn't be that aggressive.
Our Target is a little below the -0.236 Fib extension at $220.00.
-------------------------------------------------------------------------------
** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. **
-------------------------------------------------------------------------------
💸💸💸💸💸💸
👇 👇 👇 👇 👇 👇
C3.AI Is it the new PALANTIR?Last time we made an analysis on C3.ai (AI) (September 06 2024, see chart below), we gave a strong buy signal that not only did it successfully hit our $28.50 Target but also broke above the 1.5 year Channel Down:
The pattern that has emerged and looks to be what might place the strongest pressure moving on, is a Channel Up, starting from he December 2022 bottom. By early February we should also have formed the first Golden Cross on the 1W time-frame and that alone can apply high buying pressure.
Technically, the next obstacle for the stock to overcome is the Resistance Zone from the 2021 consolidation, which priced the previous High of June 2023. If the 1W MA50 (blue trend-line) holds and pushes the price above the Zone, we expect an aggressive push towards potentially the All Time High (ATH) of the stock, much like Palantir did on its own break-out. A more modest technical Target before that however, would be $130.00.
-------------------------------------------------------------------------------
** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. **
-------------------------------------------------------------------------------
💸💸💸💸💸💸
👇 👇 👇 👇 👇 👇
ASSO ALCOHOLS - Flag and Pole BreakoutNew LONG Trade Alert: Associated Alcohols
On the daily time frame, the chart looks ready to take off from here after the confirmed flag and pole breakout.
I have entered in this trade using Risological Trading Indicator.
Exit rule:
Close the long position once you get the first RED candle close using the Risological indicator.
Good luck to all!
Follow for more!
AMD Bullish break-out above the 3-month Resistance.Advanced Micro Devices (AMD) opened (and closed) yesterday above the 3-month Channel Down pattern that started after the October 09 2024 High and that is technically a strong bullish break-out signal.
The previous break-out in August 2024, eventually reached the 0.786 Fibonacci extension, which was the October 09 2024 High, before declining again.
Even though we are long-term bullish on AMD, as it even kept clear the 1W MA200 (red trend-line), which is its multi-month Support, we expect it to reach at least $160.00 (just below the 0.786 Fib) on the short-term.
-------------------------------------------------------------------------------
** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. **
-------------------------------------------------------------------------------
💸💸💸💸💸💸
👇 👇 👇 👇 👇 👇
PVRINOX PlungesPVRINOX on the 1-day timeframe demonstrated a sharp bearish move, successfully hitting all targets in a precise short trade setup. Identified using the Risological Swing Trading Indicator , this trade perfectly captured the market's downward momentum.
PVRINOX Key Levels:
Entry: ₹1520.80
SL: ₹1570.40
TP1: ₹1459.45 ✅
TP2: ₹1360.25 ✅
TP3: ₹1261.05 ✅
TP4: ₹1199.75 ✅
Technical Analysis:
The trade initiated at ₹1520.80 with a calculated stop-loss at ₹1570.40, offering an impressive risk-to-reward ratio.
The consistent downtrend was confirmed as prices respected the resistance levels marked by the Risological indicator.
The achievement of all targets reflects the trade's efficiency and the indicator's accuracy.
The break below key support levels and sustained bearish momentum ensured the targets were met seamlessly.
TSM: Growth and Charts Align for 15%+ Target?Hey Realistic Traders, Will NYSE:TSM Create a New All-Time High? Let’s Dive In....
TSMC is the world’s largest contract chipmaker. Recent Earning Call reported whooping third quarter revenue of $759.69 billion, marking a YoY increase of 36.5%. The performance is beating the market forecast. Double Digit Revenue Growth is driven by demand for AI Chips especially with major client like NVIDIA & Apple and 3-nanometer &5 nanometer technology in Smartphones. TSMC Chief Financial Officer Huang Renzhao shared optimistic project for the company. TSMC expect Q4 quarterly revenue growth of approximately 13%, sligtly above the market the market expectation.
Strong AI-Related demand predicted to persist for year, inlined with the company’s perfomance and expectation. The positive sentiment support our bullish call on NVIDIA.
Technical Analysis
On the daily timeframe, TSM has remained above the EMA200 line for over a year, maintaining its bullish trend. On August 5, 2024, TSM rebounded impulsively from the EMA200 line after completing an ABC correction pattern, signaling the start of a new bullish wave.
The second and fourth corrective waves have retraced to the Fibonacci 0.382 and 0.618 golden ratios, respectively, aligning with Elliott Wave rules that typically indicate further upward movement.
In addition to the Elliott Wave analysis, a breakout from a Descending Broadening Wedge pattern has been identified. Such breakouts often signal the continuation of the prevailing market trend.
Therefore based on these technical analysis, I foresee a potential upward movement toward the first target at $217.85 or second target at 234.46
This outlook remains valid as long as the price holds above the stop-loss level at 177.95
Support the channel by engaging with the content, using the rocket button, and sharing your opinions in the comments below.
Disclaimer: "Please note that this analysis is solely for educational purposes and should not be considered a recommendation to take a long or short position on Taiwan Semiconductor."
GameStop (GME) Can We Jump Over $33 to Reach New Heights?Hey there, trading family! Get ready for an exciting journey with GameStop (GME) stock! Right now, GME is like a video game character trying to jump over a big obstacle at $33. If it makes this jump, wow, we might see it zoom up to play between $36.50 and $37.50! It's like reaching a new level in your favorite game.
But here's the catch: if GME doesn't make it over $33, it's like falling back to the start of the level, or in this case, dropping back down to hang out between $25 and $27. We'll look at cool charts and listen to what other gamers (I mean, traders!) are saying about GME to help us guess what might happen next. Will GME soar like a high score, or will we have to retry the level?
If you found this post useful share, like or tell me your thoughts would love to hear them.
Kris/ Mindbloome Exchange
Trade What You See
"HDFC Bank Swing Trade: Key Levels & 3-Month Investment Plan"A investment idea for HDFCBANK with a holding period of up to 3 months (till Q1). Here’s the analysis based on the marked levels:
Key Levels and Strategy:
1. Entry Point:
1,719.00: Recommended entry level.
2. Take Profit (TP) Targets:
TP 1: 1,778.55
TP 2: 1,818.70
TP 3: 1,906.55 (longer-term target).
3. Stop-Loss (SL) Levels:
SL: 1,697.25 (first risk level, can act as minor support).
Strict SL: 1,671.95 (final stop-loss level to limit risk).
Observations:
Risk-Reward: This strategy provides a well-defined risk-to-reward ratio, with three potential profit levels.
Support Zone: The area around 1,697.25 - 1,671.95 is critical. It might act as strong support if the price drops further.
Resistance Levels:
1,778.55: Could face selling pressure as it aligns with prior resistance.
1,818.70: A stronger resistance where bulls need momentum to break through.
Recommendation:
If the price moves to the entry level (1,719.00), ensure to set your stop-loss and gradually book profits at the mentioned TP levels.
Reassess market conditions if it approaches strict SL (1,671.95) to avoid excessive losses.
Disclaimer:
"I'm not SEBI registered. Please take any trade at your own risk. Market securities are subject to market risks. This is for educational purposes only.
Would you like further insights into technical indicators or additional strategies?
Thank you! Subscribe and like @Alpha_strike_trader."
EXXON MOBIL Will it recover the devastating December?Exxon Mobil (XOM) gave us an excellent buy signal on our last idea (September 27 2024, see chart below) as it quickly hit our $120 Target:
Since the November 22 2024 (Lower) High though, it had an aggressive sell-of that stopped on the December 20 2024 Low. The price has stabilized for now but hasn't yet gained the necessary momentum to stage a rebound.
On the other hand, there are some very encouraging signals that justify going long as the Risk/ Reward Ratio has turned very favorable for buying. The price might not be exactly at the bottom (Higher Lows trend-line) of the Channel Up but the 1W RSI is on the 38.35 Support, which is the exact level where the it bottomed on January 19 2024, on the previous Higher Low.
At the same time, the 1D MACD has completed a Bullish Cross, which has always been a solid buy entry below the 0.0 level. As a result, even though the stock may deliver one last pull-back to test the bottom of the 14-month Channel Up, it is worth buying now as the upside is significantly higher. Our Target is the Resistance 2 level at $126.40.
-------------------------------------------------------------------------------
** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. **
-------------------------------------------------------------------------------
💸💸💸💸💸💸
👇 👇 👇 👇 👇 👇
TESLA How further can it drop??Tesla (TSLA) has clearly overachieved since our previous buy signal (August 15 2024, see chart below), surpassing our $380 Target:
The last 3 weeks though has seen overdue weakness on the price action, which was delayed due to the U.S. elections aftermath. The deliveries miss is pulling the price back towards its fair value region and the 1D MA50 (blue trend-line), which has been intact since the October 23 2024 bullish break-out.
Tesla has been trading inside a Parabolic Channel for almost a year (since February 2024) and the level that has marked the strongest buy opportunities recently has been the 1D MA100 (green trend-line). Every contact on that level since the August 05 2024 Low, has been a solid buy entry.
Parallel to the 1D MA100 contacts, the 1D RSI tends to test its own Support Zone, whose bottoms are aligned and is an additional buy signal.
With regards to corrections within this Parabolic Channel, the two major ones have both been -32.65%, an amazing display of symmetry. If the current pull-back also follows that pattern and evolves into another -32.65% Bearish Leg, then it might make contact with the 1D MA100 around the $330 level. Unless the 1D RSI hits its Support Zone earlier, that is technically a fair value for Tesla in our opinion, where heavy buying may commence again.
-------------------------------------------------------------------------------
** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. **
-------------------------------------------------------------------------------
💸💸💸💸💸💸
👇 👇 👇 👇 👇 👇
Suntek realtyFrom the Covid low of 145 zone prices have given a rally for two years and made a high of 590 in Jan'22. From there prices have retraced 50% and made a low of 272 and recovered back to hit new all time high.
Prices have made a continuation Head & shoulders pattern whose neckline is 500 zone. Prices have given the breakout the neckline and currently retesting the same. The measured target of the pattern is 950 zone.
Prices are likely to continue the uptrend towards 950-1000 zone in the coming months. The key level for the same is 380.
Ai16Z | From Meme to Money making machineai16z is the new star in the meme token galaxy, built on the lightning fast Solana blockchain and launched on the playful daos. fun platform. With AI backing it and a cheeky nod to the a16z VC fund, this token’s got serious meme mentum.
Today’s Price Check
-Current Price: $1.27 (+5% in the last 24 hours)
-All-Time High (ATH): $1.38 (hit on Dec 29, 2024) – just 5.86% below the peak.
-Circulating Supply: 1.10 billion tokens (max supply also 1.10 billion).
-24-Hour Trading Volume: A whopping $75.84 million.
Market Flex
ai16z is traded on 24 markets and 14 exchanges, with Gate.io leading the pack. It holds a cozy 0.04% share of the total crypto market, boasting a market cap of $1.43 billion. Oh, and word on the street? It’s on Binance’s radar for a potential listing
Riding the Meme Wave
Move over, SHIB, PEPE, and DOGE—ai16z is stealing the spotlight in the meme coin market rally. Its lowest price ever? A humble $0.01019 on Nov 3, 2024. Fast forward to now, and it’s up an insane 12,650% from that rock bottom price.
The Whale Tale
December 28 was a big day for ai16z, thanks to a crypto whale who made some serious moves. This savvy investor withdrew 10M USDC from Coinbase and snagged 13.16M ai16z tokens when they were undervalued on Dec 11.
The result? In just two weeks, their $10 million investment ballooned to a jaw-dropping $15.66 million, netting a sweet $5.66 million profit. That’s the kind of whale flex you all dream about.
ai16z is proving it’s more than just a meme, it’s a mover and shaker in the Solana ecosystem.
Linde plc | LIN Linde, Timeless Excellence
Linde is a timeless business with even better stability than other basic materials businesses. The company works in gases and has a near-unbroken EPS growth record of 8% annually
Linde is a market leader, and if you invest in the company, you're investing in the world's largest company for industrial gases. The company was originally a result of a takeover of British BOC in 2006, and again the 2018 merger of Linde and Praxair, a US company.
On the macro upside, there was a 1) supportive regulatory framework in the USA and in the EU on green opportunities and hydrogen, 2) the Ukraine invasion was also a key catalyst towards the energy transition, 3) the EU chip acts with €43 billion in supporting funds as well as the United States Chips and Science Act development for a value of approximately $52 billion, and 4) higher needs of specialty gas in EV car. Related to the micro upside, the company is more diversified on a GEO revenue basis and sells different product solutions starting from cylinders to bulk liquid. In addition with a follow-up note titled "Positive News Ahead", we reported Linde's lower cost structure with the Frankfort delisting. Aside from removing the dual listing expenses, we positively view this development because US companies' P/E multiple are usually higher compared to the EU one.
To support our MACRO buy case recap, in the second quarter, Linde announced two new projects with Evonik and Heidelberg Materials (both companies covered by our internal team). The company signed a long-term agreement to produce green hydrogen for Evonik in a 9-megawatt alkaline electrolyzer plant in Singapore. With Heidelberg, Linde will build a large-scale carbon capture close to the Lengfurt plant in Germany. As a reminder, cement production is estimated to be responsible for around 7% of global
in 2022, APD's earnings per share were at $8.38, and Linde's earnings per share were fairly similar at $8.23. For 2023, Air Products and Chemical EPS guide a midpoint at $11.40 while Linde's EPS is forecasted at $13.65. Looking at the ROCE, in Q4 2022, APD stood at 11.7% and Linde at 13.4%. In the last quarter, APD’s ROCE was flat on the two-year comparison, while Linde’s after-tax ROCE reached 24.0%.
While there are some business & regional nuances between the two leading companies (for instance, APD is lacking U.S. packaged gas business), here at the Lab, we believe are more inclined toward Linde, particularly when organic growth has been fairly similar. Cross-checking APD and Linde's last quarter results, we should recall that on a comparable basis, the German player volumes were flat with an average selling price up by 8%. On the other hand, APD increased its volume by 6% with an increase in the average selling price of 8% too. APD adj EBITDA grew by 13% while Linde achieved a plus 11%. However, Linde's EU exposure is greater than APD. Therefore, this is supportive of Linde's bottom line. In numbers, excluding the Engineering divisional performance, Linde's EMEA sales reached $2,177 million and represented 29.72% of the company's total sales. Compared to Q1 2022 number, turnover grew by 10% and was driven by a 13% of cost pass-through increase.
Shopify Inc | SHOP & AIShopify stock has seen sideways momentum for the last few weeks despite posting good results in the recent quarter. One of the reasons is the bull run in early 2023 due to which the stock has seen over 60% jump in year-to-date. Shopify has been able to reignite revenue growth in the last few quarters and there are strong tailwinds that can help the company improve its topline. At the same time, Shopify has been able to improve the conversion of Gross Merchandise Value or GMV into revenue due to better services. Shopify’s GMV has increased 11x between the last quarter of 2016 and the last quarter of 2022. During this time, Shopify’s quarterly revenue base has increased from $130 million to $1.7 billion or 13x.
Shopify’s GMV for 2022 was $195 billion and rapid growth in this key metric should help the company improve monetization. The company has also undertaken some cost-cutting which is having a positive impact on the bottom line. Analysts have forecasted Shopify’s EPS at $1 for fiscal 2025 which means that the stock is trading 60 times the EPS estimate of 2025. However, better monetization and focus on cost optimization could help the company deliver good EPS growth in the next few quarters. The PS ratio is also at 12 which is significantly lower than the pre-pandemic years. Shopify stock can deliver good returns in the long term as the company adds new services and improves its GMV growth trajectory.
Shopify reported a GMV of $5.5 billion in December 2016 quarter. This has increased to $60 billion in the recent December 2022 quarter. Hence, Shopify’s GMV has increased to 11 times within the last seven years. On the other hand, Shopify’s revenue during the December quarter has increased by 13 times, from $130 million to $1.7 billion. This growth trend shows that the company is able to convert more GMV into actual revenue. One of the main reasons behind this trend is that Shopify is adding new services and it can charge customers a higher commission for these services.
Shopify’s GMV for 2022 was a staggering $195 billion. The company has been able to reignite revenue growth in the last few quarters. The YoY revenue growth hit a bottom of 15% in June 2022. Since then the YoY revenue growth has picked up again as the company faces easier comps. In the recent quarter, the company reported YoY revenue growth of over 30% which is quite high when we consider that the GMV base of Shopify is more than $200 billion.
The revenue growth will not build a bullish momentum for the stock unless the company can deliver sustainable profitability. During the pandemic years, Shopify’s revenue growth and high EPS helped the stock reach its peak. The company would need to focus on profitability in the next few quarters in order to rebuild a long-term bullish rally. Shopify has divested from its logistics business which should help improve the bottom line. We should also see better monetization of current services as the company tries to build new AI tools.
The EPS estimates for 2 fiscal years ahead have steadily improved in the last few quarters. According to current consensus, Shopify should be able to deliver EPS of $1 in fiscal year 2025. However, it is highly likely that Shopify will beat these estimates as the company launches new initiatives to improve monetization of its massive GMV base. Shopify’s trailing twelve months EPS during the peak of the pandemic went to $2.6. If the company can get close to this EPS rate by 2025, we should see a significant bullish run in the stock. The recent cost-cutting should also help the company improve the bottom line. We have seen a similar trend in all the Big Tech companies who have reported a rapid growth in EPS as their headcount was reduced.
While most analysts agree over the long-term revenue growth potential of Shopify, some of them are wary of the pricey valuation of the stock. Shopify is trading at 12 times its PS ratio. This is quite high when we compare with most of the other tech players and even Shopify’s peer like Wix (WIX), Etsy (ETSY), and others. However, it should be noted that Shopify’s PS ratio is significantly lower than the average PS multiple prior to the pandemic when the stock had an average PS ratio of over 20.
Shopify’s revenue estimates for 2 fiscal years ahead is close to $10 billion which is equal to annualized revenue growth of over 25%. If we look at this metric, Shopify stock is trading at 7 times the revenue estimate of fiscal year 2025. This looks reasonable if the company can also manage to improve its EPS trend over the next few years.
The long-term tailwind from ecommerce growth is still very strong. Shopify will benefit from an increase in GMV and a higher ecommerce market share in key markets. This should help the company gain pricing leverage over other competitors and also improve its monetization momentum
Shopify has reported a faster revenue growth rate compared to its GMV growth in the last few years. This shows that the company is able to charge higher rate for additional services. There has been an acceleration in revenue growth over the last few quarters. Shopify has also divested from logistics services which were pulling down the profitability of the company.
Shopify could deliver over 20% YoY revenue growth for the next few years as the company gains from strong tailwinds within the ecommerce business. If Shopify regains its earlier ttm EPS of $2 by 2025, we could see a strong bull run within the stock. While the stock is not cheap, it seems to be reasonably valued and longer-term investors could gain a better return from Shopify, making the stock a Buy at current price.
TEVA Pharmaceutical is a BUY?As the excitement around AI continues to wane, concerns about a potential US recession grow, and the risks of a major conflict in the Middle East linger, Teva Pharmaceutical's stock is entering an accumulation phase above $18, signaling strong bullish sentiment.
Why Wall Street's bullish in this drug company ?
First, on July 31, Teva announced its financial results for the second quarter of 2024, demonstrating that the company remains resilient despite years of investor disappointment following the Allergan Generics acquisition and the loss of Copaxone exclusivity.
However, over the past 18 months, under Richard Francis' leadership, the company has shown significant growth, with increasing revenue and profits in its European and US segments, the successful launch of biosimilars and Uzedy, and record sales of Austedo, its blockbuster treatment for certain neurological disorders.
Alongside rising sales of generics, Teva has also accelerated the development of innovative medications, which could set new standards in treating schizophrenia and some chronic inflammatory diseases.
For instance, on July 25, the company delighted investors by announcing that it had completed patient enrollment ahead of schedule in a Phase 2b clinical trial assessing the efficacy and safety of duvakitug for treating ulcerative colitis and Crohn's disease, driven by strong interest from healthcare professionals and patients.
Teva Pharmaceutical's financial performance and 2024 outlook
After years of challenges, the Teva revenue exceeded $4 billion once again, reaching $4.14 billion in the second quarter of 2024, a 7.4% year-on-year increase that surpassed consensus estimates by $114 million.
Meanwhile, another critical financial metric, earnings per share aka EPS, exceeded my expectations despite rising costs associated with conducting expensive clinical trials for assessing the efficacy of Teva's biosimilars and experimental drugs targeting neurodegenerative and autoimmune disorders. The Israeli company's EPS reached $0.61 for the three months ending June 30, 2024, marking a 27.1% increase from the previous quarter and surpassing analysts' forecasts by six cents.
What factors contribute to Teva Pharmaceutical's success?
To answer this objectively, it's essential to examine not only the impact of sales from individual medications but also to delve deeper into how effectively the company's management is handling the development of each of Teva's business segments.
We'll begin with the United States segment, which significantly influences Teva's financial standing. For the three months ending June 30, 2024, revenue in this segment reached $2.12 billion, reflecting an 11.5% year on year increase and a 22.3% rise from the previous quarter.
First, Teva's revenue and profit growth were largely fueled by significant advancements in its generics business, despite facing stiff competition from companies like Viatris (VTRS), Dr. Reddy's Laboratories (RDY), Perrigo (PRGO), and others in the market.
In the second quarter, total sales of generic products reached approximately $1.03 billion, marking a 26.6% increase from the previous quarter.
What factors led to the recovery of Teva's generics business?
The resurgence of Teva's generics business in the U.S. was primarily driven by the launch of an interchangeable biosimilar to AbbVie's Humira (ABBV), rising demand for generic versions of Bristol-Myers Squibb's Revlimid (BMY), a major blockbuster for treating multiple myeloma, the generic version of Novo Nordisk's Victoza (NVO) for type 2 diabetes, and the expansion of its drug portfolio.
The soaring sales of Copaxone and the strong performance of Austedo, which I analyzed in detail in a previous article, were also notable. Despite increasing competition in the U.S. tardive dyskinesia therapeutics market from Neurocrine Biosciences' (NBIX) Ingrezza, Austedo's demand continued to grow.
Sales of the Austedo franchise reached $407 million in the second quarter of 2024, a 32.1% YOY increase, driven by expanded patient access and the FDA's late May approval of Austedo XR in four new tablet strengths, giving doctors more options for optimizing treatment regimens for adults with tardive dyskinesia and Huntington's disease-associated chorea.
I also want to highlight Uzedy, a long-acting formulation of risperidone, as another key contributor to Teva's revenue growth. Although the company launched Uzedy in May 2023 and has not yet disclosed its sales figures, it has been approved for the treatment of schizophrenia.
However, as evident from the chart below, the total number of prescriptions has been steadily increasing month over month. Teva Pharmaceutical estimates that its revenue from Uzedy will be around $80 million in 2024, exceeding my expectations by approximately $25 million.
Despite ongoing growth in demand for this anti-CGRP migraine medication, its sales amounted to $42 million in the second quarter of 2024, a decrease of 6.7% compared to the previous quarter and 19.2% year-on-year. This decline was primarily due to an increase in sales allowances linked to a one-time event.
Now, let's turn our attention to the company's Europe segment, which generates most of its revenue through sales of generics and biosimilars.
For the three months ending June 30, 2024, sales in this segment reached approximately $1.21 billion, reflecting a 4.3% year-on-year increase, driven by new product launches and growing demand for Ajovy.
However, sales of respiratory medications continue to face challenges due to a decline in cold and flu cases. As anticipated, demand for Copaxone is weakening, not only because of competition from generic versions but also due to the availability of more effective treatments for relapsing forms of multiple sclerosis, such as Bristol-Myers Squibb's Zeposia, Roche Holding's Ocrevus and TG Therapeutics' Briumvi (TGTX).
Lastly, let's discuss the International Markets segment, which focuses on commercializing Teva's drugs across 35 countries, including Canada and Japan. In the second quarter, revenue for this segment was $593 million, representing a 2.6% YOY increase.
However, the segment's profit dropped significantly to $73 million quarter over quarter, due to declining demand for Copaxone, increased R&D expenses, and higher sales and marketing costs related to the distribution of Austedo in China.
The question arises: "Are there any positives?" The short answer is yes.
Teva's revenue from generic drugs has been on an upward trend in recent years, with the exception of the fourth quarter of 2023. For the three months ending June 30, 2024, it reached $488 million, marking a 2% increase from the previous quarter.
What is driving this sales growth?
Despite challenges such as the weakening of foreign currencies like the Japanese yen, ruble, and Chinese yuan against the US dollar, increased competition in Japan, and ongoing inflationary pressures on the pharmaceutical industry, Teva’s management has successfully navigated these obstacles by expanding its medication portfolio and raising prices.
Now lets talk about Risks
Several risks could negatively impact Teva Pharmaceutical’s investment appeal in the medium to long term. At the end of July, Teva reported financial results for the second quarter of 2024, which not only exceeded analysts' expectations but also reinforced confidence in the effectiveness of the business strategies implemented by CEO Richard Francis.
In addition to accelerating the recovery of the company's generics business, boosting sales of Austedo and Uzedy, and launching the Humira biosimilar in May, Teva also raised its full-year 2024 guidance.
With a P/E ratio of 6.35x, which suggests the stock is trading at a discount compared to the broader healthcare sector, other positives include the reduction of Teva’s net debt by about $2 billion over the past 12 months, as well as year-over-year growth in gross and operating profits.
To understand who truly holds control over Teva Pharmaceutical Industries Limited, it's crucial to examine the company's ownership structure. The largest share of ownership, approximately 69%, is held by institutional investors. This means that this group stands to experience the greatest potential for gains or losses, depending on the company's performance.
The company has also accelerated the development of its product candidates under its "Pivot to Growth" program, which aims to strengthen its balance sheet and enhance its investment appeal by expanding its biosimilar portfolio and bringing potential best-in-class drugs for cancer, neurological, and autoimmune disorders to market.
So TEVA Pharmaceutical is a BUY? YUP
COINBASE approaching the 1W MA50 and turns into a Buy again.Coinbase (COIN) has gone a long way since our September 09 buy signal (see chart below):
Even though it marginally missed the $360 Target, the pattern served in an excellent way those investors who bought at the bottom of its dominant 2-year Channel Up. The September - December Bullish Leg was by a narrow margin, the shortest (+141.45%) of Coinbase's total 5 major rallies within this pattern.
As the price is yet again approaching the 1W MA50 (blue trend-line), it is gradually turning into a Buy opportunity again. Even though the shortest Bearish Leg has been -38.74% and that currently places the projected bottom level a little over $215, the 1W RSI has already broken below its MA (yellow trend-line), which has been the ultimate buy signal on all previous technical corrections with the exception of last April.
As a result, there are more probabilities to see COIN resume the 2-year bullish trend, with the Risk/ Reward Ratio (RRR) turning favorable again. A Dollar-cost-averaging strategy is also suited for those seeking less risk.
Our Target from now on is $500, which represents a +141.45% rise (as mentioned above, the shortest within the Channel Up).
-------------------------------------------------------------------------------
** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. **
-------------------------------------------------------------------------------
💸💸💸💸💸💸
👇 👇 👇 👇 👇 👇
